Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Faron Pharmaceuticals Oy ( (GB:FARN) ) has provided an announcement.
Faron Pharmaceuticals’ extraordinary general meeting in Turku, Finland, authorized the board to proceed with a rights offering of up to 80,000,000 new shares. The authorization, valid until 30 June 2026, allows existing shareholders to subscribe on a pre-emptive basis, with any unsubscribed shares potentially placed with other investors or guarantors.
The board has broad discretion to set key terms of the capital raise, including pricing and timetable, and may temporarily issue shares to the company itself to facilitate delivery to underwriting parties. This flexibility strengthens Faron’s ability to secure funding to advance its oncology pipeline, particularly bexmarilimab, without revoking previously granted share issuance authorities.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company developing innovative cancer immunotherapies that harness the patient’s own immune system. Its lead asset, bexmarilimab, is an investigational Clever-1–targeting antibody being evaluated in the Phase I/II BEXMAB trial for acute myeloid leukemia and myelodysplastic syndrome alongside standard-of-care treatments.
Find detailed analytics on FARN stock on TipRanks’ Stock Analysis page.